FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387187870> ?p ?o ?g. }

• W4387187870 endingPage "121" @default.
• W4387187870 startingPage "115" @default.
• W4387187870 abstract "Background: Introduction of immune checkpoint inhibitors in the standard of care for metastatic renal cell carcinoma (mRCC) requires robust but yet simple biomarkers to predict efficacy of immunotherapy. Objective: The aim of this study was to evaluate the association between fibrinogen levels and efficacy of second-line therapy with nivolumab in mRCC. Methods: This is a prospective multicenter biomarker study. Fibrinogen levels were measured one week prior to second-line nivolumab therapy and six times monthly. A high fibrinogen level was defined as ≥5 g/L. Patients were divided into two cohorts: high (H) and normal (N) fibrinogen levels. The primary endpoint was overall survival (OS). Results: The median OS was 31.5 months (95% confidence interval [CI], 27.9 to 35.1) in cohort N vs. 20.9 months (95% CI, 18.1 to 23.7) in cohort H (hazard ratio [HR], 0.39; 98.5% CI, 0.21 to 0.7; P = 0.002). The median progression-free survival was 9.4 months (95% CI, 5.5 to 14.1) in cohort N and 4.0 months (95% CI, 2.9 to 5.1) in cohort H (HR, 0.65; 95% CI, 0.51 to 0.72; P < 0.001). The objective response rate was higher in N cohort (33% vs. 17% ; P = 0.012). No statistically significant changes of fibrinogen concentration during nivolumab therapy were found. Conclusion: The study demonstrated an association of hyperfibrinogenemia with worse clinical outcomes of second-line nivolumab monotherapy in patients with mRCC. Further validation of fibrinogen as a predictive biomarker for immunotherapy efficacy in patients with mRCC is warranted." @default.
• W4387187870 created "2023-09-30" @default.
• W4387187870 creator A5000644939 @default.
• W4387187870 creator A5011318421 @default.
• W4387187870 creator A5021884582 @default.
• W4387187870 creator A5043821813 @default.
• W4387187870 creator A5048104251 @default.
• W4387187870 creator A5070988170 @default.
• W4387187870 creator A5071448884 @default.
• W4387187870 creator A5082076153 @default.
• W4387187870 creator A5082700342 @default.
• W4387187870 creator A5092969190 @default.
• W4387187870 date "2023-10-06" @default.
• W4387187870 modified "2023-10-09" @default.
• W4387187870 title "Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial" @default.
• W4387187870 cites W1596065641 @default.
• W4387187870 cites W2008589296 @default.
• W4387187870 cites W2023699475 @default.
• W4387187870 cites W2041013739 @default.
• W4387187870 cites W2055229817 @default.
• W4387187870 cites W2080167098 @default.
• W4387187870 cites W2128801971 @default.
• W4387187870 cites W2139660685 @default.
• W4387187870 cites W2148760546 @default.
• W4387187870 cites W2166383168 @default.
• W4387187870 cites W2570369313 @default.
• W4387187870 cites W3006479488 @default.
• W4387187870 cites W3007290231 @default.
• W4387187870 cites W3038844630 @default.
• W4387187870 cites W3042347895 @default.
• W4387187870 cites W4292489249 @default.
• W4387187870 cites W4309865437 @default.
• W4387187870 cites W4323975494 @default.
• W4387187870 cites W4362458477 @default.
• W4387187870 cites W4378195066 @default.
• W4387187870 cites W4386002403 @default.
• W4387187870 cites W4386157100 @default.
• W4387187870 doi "https://doi.org/10.3233/kca-230007" @default.
• W4387187870 hasPublicationYear "2023" @default.
• W4387187870 type Work @default.
• W4387187870 citedByCount "0" @default.
• W4387187870 crossrefType "journal-article" @default.
• W4387187870 hasAuthorship W4387187870A5000644939 @default.
• W4387187870 hasAuthorship W4387187870A5011318421 @default.
• W4387187870 hasAuthorship W4387187870A5021884582 @default.
• W4387187870 hasAuthorship W4387187870A5043821813 @default.
• W4387187870 hasAuthorship W4387187870A5048104251 @default.
• W4387187870 hasAuthorship W4387187870A5070988170 @default.
• W4387187870 hasAuthorship W4387187870A5071448884 @default.
• W4387187870 hasAuthorship W4387187870A5082076153 @default.
• W4387187870 hasAuthorship W4387187870A5082700342 @default.
• W4387187870 hasAuthorship W4387187870A5092969190 @default.
• W4387187870 hasBestOaLocation W43871878701 @default.
• W4387187870 hasConcept C121608353 @default.
• W4387187870 hasConcept C126322002 @default.
• W4387187870 hasConcept C143998085 @default.
• W4387187870 hasConcept C185592680 @default.
• W4387187870 hasConcept C188816634 @default.
• W4387187870 hasConcept C203092338 @default.
• W4387187870 hasConcept C207103383 @default.
• W4387187870 hasConcept C2777472916 @default.
• W4387187870 hasConcept C2777701055 @default.
• W4387187870 hasConcept C2779036427 @default.
• W4387187870 hasConcept C2780030458 @default.
• W4387187870 hasConcept C2781197716 @default.
• W4387187870 hasConcept C44249647 @default.
• W4387187870 hasConcept C50382708 @default.
• W4387187870 hasConcept C535046627 @default.
• W4387187870 hasConcept C55493867 @default.
• W4387187870 hasConcept C71924100 @default.
• W4387187870 hasConcept C72563966 @default.
• W4387187870 hasConcept C90924648 @default.
• W4387187870 hasConceptScore W4387187870C121608353 @default.
• W4387187870 hasConceptScore W4387187870C126322002 @default.
• W4387187870 hasConceptScore W4387187870C143998085 @default.
• W4387187870 hasConceptScore W4387187870C185592680 @default.
• W4387187870 hasConceptScore W4387187870C188816634 @default.
• W4387187870 hasConceptScore W4387187870C203092338 @default.
• W4387187870 hasConceptScore W4387187870C207103383 @default.
• W4387187870 hasConceptScore W4387187870C2777472916 @default.
• W4387187870 hasConceptScore W4387187870C2777701055 @default.
• W4387187870 hasConceptScore W4387187870C2779036427 @default.
• W4387187870 hasConceptScore W4387187870C2780030458 @default.
• W4387187870 hasConceptScore W4387187870C2781197716 @default.
• W4387187870 hasConceptScore W4387187870C44249647 @default.
• W4387187870 hasConceptScore W4387187870C50382708 @default.
• W4387187870 hasConceptScore W4387187870C535046627 @default.
• W4387187870 hasConceptScore W4387187870C55493867 @default.
• W4387187870 hasConceptScore W4387187870C71924100 @default.
• W4387187870 hasConceptScore W4387187870C72563966 @default.
• W4387187870 hasConceptScore W4387187870C90924648 @default.
• W4387187870 hasIssue "1" @default.
• W4387187870 hasLocation W43871878701 @default.
• W4387187870 hasOpenAccess W4387187870 @default.
• W4387187870 hasPrimaryLocation W43871878701 @default.
• W4387187870 hasRelatedWork W2792937256 @default.
• W4387187870 hasRelatedWork W2955056171 @default.
• W4387187870 hasRelatedWork W2966932534 @default.

• next